サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1370911

クリプトコッカス症治療薬市場、-世界の産業規模、シェア、動向、機会、および予測、2018-2028年治療別、流通チャネル別、地域別、競合別にセグメント化

Cryptococcosis Therapeutics Market, - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment, By Distribution Channel, By Region, By Competition.
出版日: | 発行: TechSci Research | ページ情報: 英文 190 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

クリプトコッカス症治療薬市場、-世界の産業規模、シェア、動向、機会、および予測、2018-2028年治療別、流通チャネル別、地域別、競合別にセグメント化
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 190 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

クリプトコッカス症治療薬の世界市場は、2022年に46億7,000万米ドルと評価され、2028年までのCAGRは4.34%と着実な成長を示し、2028年には60億4,000万米ドルに達すると予測されています。

クリプトコッカス症は、主に肺および中枢神経系の感染症として現れ、軽度の呼吸器系の問題から重度の神経学的合併症まで幅広い症状を示します。原因となる真菌は環境中、特に鳥の糞で汚染された土壌に多く存在します。真菌の胞子を吸い込むと、特にそのような状態になりやすい人に感染症を引き起こす可能性があります。HIV/AIDSの流行、臓器移植、その他の免疫抑制状態などの要因により、免疫不全患者が増加していることが、クリプトコッカス症の負担の増大に大きく寄与しています。研究努力の結果、治療法の選択肢が改善され続けているため、クリプトコッカス症治療薬市場は成長の態勢を整えています。製薬会社、学術機関、公開医療機関が協力する取り組みは、これらの技術革新を進める上で極めて重要です。新たな抗真菌剤、併用療法、製剤の出現により、クリプトコッカス症に罹患した患者の見通しは改善し、生活の質と生存率が向上すると予想されます。

主な市場促進要因

免疫不全状態の有病率の上昇がクリプトコッカス症治療薬市場を牽引：近年、免疫不全状態に苦しむ人の数が顕著に急増しています。世界のHIV/AIDSの流行は、依然としてクリプトコッカス症の有病率に大きく寄与しています。HIVの治療と予防が飛躍的に進歩したにもかかわらず、依然として多くの患者が適切な医療を受けられず、クリプトコッカス症などの日和見感染症に罹患しやすくなっています。臓器移植やがん治療の普及は、患者に新たな希望を与えると同時に、免疫系を弱体化させています。医療の進歩により、臓器移植を受けた患者やがんを克服した患者の寿命が延びるにつれ、免疫力が低下した状態で生活する人口が増加しています。このような免疫不全患者におけるクリプトコッカス症有病率の上昇傾向は、クリプトコッカス症治療薬の開発に拍車をかけています。その結果、この市場では研究開発が急増しています。製薬会社は、より効果的で毒性が低く、より幅広い患者層が利用できる薬剤の創製に努めています。クリプトコッカス症の注目すべき治療法には、アムホテリシンB、フルコナゾール、フルシトシンなどの抗真菌薬があります。しかし、これらの薬剤は有効性や潜在的な副作用の点で限界があり、革新的な治療法の必要性が高まっています。研究者は、治療成績を向上させ、免疫不全患者におけるクリプトコッカス症の負担を軽減するために、新規抗真菌化合物、併用療法、免疫調整剤の探索を積極的に行っています。

市場概要
予測期間 2024-2028
市場規模2022年 46億7,000万米ドル
2028年の市場規模 60億4,000万米ドル
CAGR 2023-2028 4.34%
急成長セグメント フルシトシン
最大市場 北米

公衆衛生意識の高まりがクリプトコッカス症治療薬市場を促進公衆衛生意識の高まりにより、効果的なクリプトコッカス症治療薬への需要が高まっています。この需要がクリプトコッカス症治療薬市場の成長を促しています。製薬会社や研究者は、この真菌感染症と闘い、患者の生活の質を高める革新的な治療法の必要性を認識しています。市場がより効果的な治療法を提供しようと努める中、研究開発への投資は大幅に急増しました。このため、新薬候補の探索、治療アプローチ、臨床試験が活発化しています。新規抗真菌剤、併用療法、免疫調節療法の開発は、世界のクリプトコッカス症の負担に対処する緊急性の高まりによって推進されています。公衆衛生に対する意識は、学界、製薬会社、研究機関の協力に火をつけた。クリプトコッカス症が単なる医学的課題ではなく、社会的課題であるとの認識が、利害関係者を革新的な解決策への協力へと駆り立てています。クリプトコッカス症治療薬の分野を前進させるために、研究パートナーシップ、政府イニシアティブ、非営利団体がリソースを出し合っています。さらに、公衆衛生に対する意識の高まりが、ベンチャーキャピタルや資金提供団体からの投資を集めています。大幅な市場拡大の可能性と、生命を脅かす感染症に対処するという人道的側面が相まって、調査や臨床試験に対する資金援助が行われています。

真菌感染症の複雑性が重要な課題となっている：クリプトコッカス症のような真菌感染症は複雑で、効果的な治療法を開発するためには、真菌の生物学、宿主との相互作用、耐性メカニズムを深く理解する必要があります。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 クリプトコッカス症治療薬の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療薬別（アムホテリシンB、フルシトシン、フルコナゾール、その他）
    • 流通チャネル別（病院、小売薬局、専門クリニック、その他）
    • 地域別
    • 企業別（主要5社シェア）
  • 市場マップ
    • 治療薬別
    • 流通チャネル別
    • 地域別

第6章 北米クリプトコッカス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療薬別
    • 販売チャネル別
    • 国別

第7章 欧州クリプトコッカス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療薬別
    • 流通チャネル別
    • 国別

第8章 アジア太平洋クリプトコッカス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療薬別
    • 流通チャネル別
    • 国別

第9章 南米クリプトコッカス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 流通チャネル別
    • 国別

第10章 中東・アフリカクリプトコッカス症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 流通チャネル別
    • 国別

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の展開
  • 合併・買収
  • 治療薬の上市

第13章 競合情勢

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc.（Johnson & Johnson Services, Inc.）
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

第14章 戦略的提言

第15章 調査会社について・免責事項

目次
Product Code: 15909

The Global Cryptococcosis Therapeutics Market, valued at USD 4.67 Billion in 2022, is expected to exhibit steady growth with a CAGR of 4.34% through 2028 and expected to reach USD 6.04 Billion in 2028. Cryptococcosis predominantly manifests as a pulmonary and central nervous system infection, exhibiting symptoms ranging from mild respiratory issues to severe neurological complications. The causative fungus is commonly found in the environment, particularly in soil contaminated by bird droppings. When inhaled, the fungal spores can lead to infections, especially in individuals susceptible to such conditions. The increasing prevalence of immunocompromised patients, driven by factors like the HIV/AIDS epidemic, organ transplants, and other immunosuppressive states, has significantly contributed to the escalating burden of cryptococcosis. As research endeavors continue to yield improved treatment options, the cryptococcosis therapeutics market is poised for growth. Collaborative efforts involving pharmaceutical companies, academic institutions, and public health organizations will be pivotal in advancing these innovations. With the emergence of new antifungal agents, combination therapies, and formulations, the outlook for individuals affected by cryptococcosis is expected to improve, enhancing their quality of life and survival rates.

Primary Market Drivers

Rising Prevalence of Immunocompromised Conditions Drives the Cryptococcosis Therapeutics Market: In recent years, there has been a noticeable surge in the number of individuals grappling with immunocompromised conditions. The global HIV/AIDS epidemic remains a significant contributor to the prevalence of cryptococcosis. Despite strides in HIV treatment and prevention, many individuals still lack access to adequate healthcare, rendering them susceptible to opportunistic infections such as cryptococcosis. The increasing prevalence of organ transplantation and cancer treatments offers newfound hope to patients while simultaneously weakening their immune systems. As medical advancements extend the lifespans of organ transplant recipients and cancer survivors, the population living with compromised immune systems is on the rise. This upward trajectory in cryptococcosis prevalence among immunocompromised individuals has catalyzed the development of cryptococcosis therapeutics. Consequently, this market has witnessed a surge in research and development endeavors. Pharmaceutical companies are striving to create drugs that are more effective, less toxic, and accessible to a broader patient base. Notable treatment options for cryptococcosis include antifungal drugs like amphotericin B, fluconazole, and flucytosine. However, these medications may have limitations in terms of efficacy and potential side effects, driving the need for innovative therapeutic solutions. Researchers are actively exploring novel antifungal compounds, combination therapies, and immune-modulating agents to enhance treatment outcomes and alleviate the burden of cryptococcosis among immunocompromised patients.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.67 Billion
Market Size 2028USD 6.04 Billion
CAGR 2023-20284.34%
Fastest Growing SegmentFlucytosine
Largest MarketNorth America

Rising Public Health Awareness Propels the Cryptococcosis Therapeutics Market: The upsurge in public health awareness has correspondingly generated demand for effective cryptococcosis treatments. This demand, in turn, has stimulated growth within the cryptococcosis therapeutics market. Pharmaceutical companies and researchers have recognized the necessity for innovative therapies to combat this fungal infection and enhance patients' quality of life. Investments in research and development have surged substantially as the market endeavors to offer more effective treatments. This has instigated the exploration of new drug candidates, therapeutic approaches, and clinical trials. The development of novel antifungal agents, combination therapies, and immunomodulatory treatments has been driven by the growing urgency to address the global cryptococcosis burden. Public health awareness has sparked collaboration between academia, pharmaceutical firms, and research institutions. The recognition that cryptococcosis is not just a medical challenge but a societal issue has motivated stakeholders to collaborate on innovative solutions. Research partnerships, governmental initiatives, and nonprofit organizations are pooling resources to advance the field of cryptococcosis therapeutics. Furthermore, heightened public health awareness has garnered investment from venture capitalists and funding organizations. The potential for substantial market expansion, coupled with the humanitarian aspect of addressing a life-threatening infection, has resulted in financial support for research and clinical trials.

Complexity of Fungal Infections Presents Key Challenges: Fungal infections like cryptococcosis are intricate, requiring a profound understanding of fungal biology, host interactions, and resistance mechanisms to develop effective treatments.

Clinical Trial Design Poses Challenges: Conducting clinical trials for antifungal drugs is challenging due to the need for specialized patient populations and appropriate study endpoints.

Affordability and Access Remain Significant Challenges: Ensuring that innovative treatments are affordable and accessible, particularly in resource-limited settings, remains a crucial challenge.

Technological Advancements Drive Market Trends: Advancements in diagnostic techniques have revolutionized cryptococcosis detection, leading to earlier and more accurate diagnoses. Molecular diagnostic methods like polymerase chain reaction (PCR) have enabled the detection of Cryptococcus DNA in patient samples. PCR amplifies specific DNA sequences, enabling the detection of even small amounts of fungal DNA. This technique's sensitivity allows for the identification of the fungus in blood or cerebrospinal fluid, facilitating swift diagnosis and treatment initiation. Antigen detection assays have proven valuable for diagnosing cryptococcosis. These assays identify specific fungal antigens, such as Cryptococcus' capsular polysaccharide, in patient samples. Antigen detection tests are highly sensitive and can be conducted on blood or cerebrospinal fluid, aiding in early infection detection. Advanced imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI) have enhanced the visualization of fungal infections within the body, especially when they have spread to the central nervous system.

Segmental and Regional Insights: The Flucytosine segment dominated the Cryptococcosis Therapeutics market in 2022 and is predicted to continue its expansion. Hospitals, particularly in North America, play a pivotal role in prompt cryptococcosis diagnosis and treatment, owing to their advanced healthcare infrastructure.

Key Market Players

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

Report Scope:

  • In this report, the Global Cryptococcosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Cryptococcosis Therapeutics Market, By Treatment:

  • Amphotericin B
  • Flucytosine
  • Fluconazole
  • Other

Cryptococcosis Therapeutics Market, By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Specialty Clinics
  • Others

Cryptococcosis Therapeutics Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Cryptococcosis Therapeutics Market.

Available Customizations:

  • Global Cryptococcosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cryptococcosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Amphotericin B, Flucytosine, Fluconazole, Others)
    • 5.2.2. By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Cryptococcosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
      • 6.2.3.1. United States Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.1.1. Market Size & Forecast
        • 6.2.3.1.1.1. By Value
        • 6.2.3.1.2. Market Share & Forecast
        • 6.2.3.1.2.1. By Treatment
        • 6.2.3.1.2.2. By Distribution Channel
      • 6.2.3.2. Canada Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.2.1. Market Size & Forecast
        • 6.2.3.2.1.1. By Value
        • 6.2.3.2.2. Market Share & Forecast
        • 6.2.3.2.2.1. By Treatment
        • 6.2.3.2.2.2. By Distribution Channel
      • 6.2.3.3. Mexico Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.3.1. Market Size & Forecast
        • 6.2.3.3.1.1. By Value
        • 6.2.3.3.2. Market Share & Forecast
        • 6.2.3.3.2.1. By Test
        • 6.2.3.3.2.2. By Distribution Channel

7. Europe Cryptococcosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2.
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. France Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Treatment
        • 7.2.4.1.2.2. By Distribution Channel
      • 7.2.4.2. Germany Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Treatment
        • 7.2.4.2.2.2. By Distribution Channel
      • 7.2.4.3. United Kingdom Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Treatment
        • 7.2.4.3.2.2. By Distribution Channel
      • 7.2.4.4. Italy Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Treatment
        • 7.2.4.4.2.2. By Distribution Channel
      • 7.2.4.5. Spain Cryptococcosis Therapeutics Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Treatment
        • 7.2.4.5.2.2. By Distribution Channel

8. Asia Pacific Cryptococcosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
      • 8.2.3.1. China Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.1.1. Market Size & Forecast
        • 8.2.3.1.1.1. By Value
        • 8.2.3.1.2. Market Share & Forecast
        • 8.2.3.1.2.1. By Treatment
        • 8.2.3.1.2.2. By Distribution Channel
      • 8.2.3.2. India Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.2.1. Market Size & Forecast
        • 8.2.3.2.1.1. By Value
        • 8.2.3.2.2. Market Share & Forecast
        • 8.2.3.2.2.1. By Treatment
        • 8.2.3.2.2.2. By Distribution Channel
      • 8.2.3.3. South Korea Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.3.1. Market Size & Forecast
        • 8.2.3.3.1.1. By Value
        • 8.2.3.3.2. Market Share & Forecast
        • 8.2.3.3.2.1. By Treatment
        • 8.2.3.3.2.2. By Distribution Channel
      • 8.2.3.4. Japan Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.4.1. Market Size & Forecast
        • 8.2.3.4.1.1. By Value
        • 8.2.3.4.2. Market Share & Forecast
        • 8.2.3.4.2.1. By Treatment
        • 8.2.3.4.2.2. By Distribution Channel
      • 8.2.3.5. Australia Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.5.1. Market Size & Forecast
        • 8.2.3.5.1.1. By Value
        • 8.2.3.5.2. Market Share & Forecast
        • 8.2.3.5.2.1. By Treatment
        • 8.2.3.5.2.2. By Distribution Channel

9. South America Cryptococcosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2.
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Treatment
        • 9.2.4.1.2.2. By Distribution Channel
      • 9.2.4.2. Argentina Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Treatment
        • 9.2.4.2.2.2. By Distribution Channel
      • 9.2.4.3. Colombia Cryptococcosis Therapeutics Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Treatment
        • 9.2.4.3.2.2. By Distribution Channel

10. Middle East & Africa Cryptococcosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
      • 10.2.3.1. South Africa Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.1.1. Market Size & Forecast
        • 10.2.3.1.1.1. By Value
        • 10.2.3.1.2. Market Share & Forecast
        • 10.2.3.1.2.1. By Treatment
        • 10.2.3.1.2.2. By Distribution Channel
      • 10.2.3.2. Saudi Arabia Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.2.1. Market Size & Forecast
        • 10.2.3.2.1.1. By Value
        • 10.2.3.2.2. Market Share & Forecast
        • 10.2.3.2.2.1. By Treatment
        • 10.2.3.2.2.2. By Distribution Channel
      • 10.2.3.3. UAE Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.3.1. Market Size & Forecast
        • 10.2.3.3.1.1. By Value
        • 10.2.3.3.2. Market Share & Forecast
        • 10.2.3.3.2.1. By Treatment
        • 10.2.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Treatment Launches

13. Competitive Landscape

  • 13.1. Astellas Pharma Inc
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. Glenmark Pharmaceuticals
  • 13.4. Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • 13.5. Novartis AG
  • 13.6. Pfizer Inc
  • 13.7. Asahi Kasei Pharma
  • 13.8. Sigmapharm Laboratories LLC

14. Strategic Recommendations

15. About us & Disclaimer